보고서 요약(국문)

개요
전 세계 비낭포성 섬유증 기관지확장증(NCFB) 치료 시장은 2022년 YY백만 달러에 달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) YY%로 성장하여 2030년에는 YY백만 달러에 이를 것으로 예상됩니다.

비낭포성 섬유증 기관지확장증(NCFB)은 만성적이고 진행성인 호흡기 질환으로, 비가역적이고 비정상적으로 확장된 기도, 지속적인 기침, 과도한 가래 생성, 재발성 폐 감염이 특징입니다. 폐렴, 섬모 이상, 면역 결핍 등 다양한 원인으로 발생할 수 있으며, 주로 노인에게 발생합니다. NCFB 환자는 일반적으로 이환율이 높고 삶의 질이 저하됩니다.
또한, NCFB는 완치할 수는 없지만 치료를 통해 관리할 수 있습니다. 치료에는 다양한 종류의 기도 청소 장치(예: 조끼형 기도 청소 시스템 및 양압 호기 밸브)를 이용한 기도 청소가 포함되며, 폐렴구균 및 인플루엔자 백신 접종, 마크로라이드계 항생제를 사용하여 기도 점액 분비 및 점도를 감소시키고, 항생제를 사용하여 세균 부하를 줄이고 염증 지표를 대부분 감소시킵니다. 또한 물리 치료, 폐 재활 및 기관지 확장제를 사용하여 질환의 중증도를 관리합니다.
시장 동향: 성장 요인
규제 승인 증가 및 신약 출시
규제 승인 증가와 신약 출시가 예측 기간 동안 시장 성장을 견인할 것으로 예상됩니다. FDA 승인과 같은 규제 승인은 새로운 약물과 치료법이 안전하게 시장에 진입할 수 있도록 길을 열어줍니다. 이러한 치료 옵션의 확대는 환자에게 더 많은 선택권을 제공하고, 개별 환자의 요구와 특성에 따른 맞춤형 치료 계획을 수립할 수 있도록 합니다. 이러한 규제 승인은 신약 사용에 대한 환자의 신뢰를 높여줍니다.

예를 들어, 심각하고 희귀한 질환을 앓는 환자들의 삶을 변화시키는 것을 사명으로 하는 글로벌 바이오제약 회사인 인스메드(Insmed Incorporated)는 2020년 6월 8일, 미국 식품의약국(FDA)이 비낭성 섬유증 기관지확장증(NCFB) 성인 환자의 악화 감소 치료를 위한 브렌소카팁(이전 명칭 INS1007)에 대해 혁신 치료제 지정을 승인했다고 발표했습니다.
또한, NCFB 관리에 더 나은 결과를 보이는 신약 개발을 위한 많은 임상 시험이 진행 중입니다. 신약은 효능과 안전성을 입증하기 위해 임상 시험을 거치는 경우가 많습니다. 예를 들어, 레노비온(Renovion, Inc.)은 2022년 11월, 비낭성 섬유증 기관지확장증(NCFB) 성인 환자 치료를 위한 분무형 치료제인 ARINA-1의 2상 임상 연구에 첫 번째 환자가 등록했다고 발표했습니다.

또한, 2022년 2월 22일, 아르마타 파마슈티컬스(Armata Pharmaceuticals, Inc.)는 미국 식품의약국(FDA)이 자사의 최적화된 주요 치료 후보 물질인 AP-PA02의 두 번째 적응증인 비낭성 섬유증 기관지확장증(NCFB)에 대한 2상 임상 시험 개시를 위한 임상시험계획승인신청(IND)을 승인했다고 발표했습니다.
더 나아가, 비낭성 섬유증 기관지확장증의 유병률 증가, 임상 시험 증가, 네뷸라이저 사용 증가, 물리 치료 및 기도 청소 장치의 기술 발전, 인식 제고 및 새로운 치료법 개발의 진전은 예측 기간 동안 시장 성장을 견인할 것으로 예상되는 요인입니다.

제한 요인
치료 약물과 관련된 합병증, 높은 치료 비용, 물리 치료와 관련된 부작용, 더 나은 적절한 치료법의 부족, 대체 치료법의 존재 등은 시장 성장을 저해할 것으로 예상됩니다.

시장 세분화 분석
전 세계 비낭포성 섬유증 기관지확장증(NCFB) 치료 시장은 치료 유형, 투여 경로, 판매 채널 및 지역별로 세분화됩니다.
기도 청소 부문은 비낭포성 섬유증 기관지확장증(NCFB) 치료 시장 점유율의 약 46.2%를 차지했습니다.
기도 청소 부문은 예측 기간 동안 가장 큰 시장 점유율을 차지할 것으로 예상됩니다. 비낭포성 섬유증 기관지확장증은 완치할 수 없지만, 기도 청소 치료는 질병 관리 및 중증도 조절에 가장 일반적으로 사용됩니다. 환자들은 종종 가정에서 기도 청소 기술을 수행하도록 교육받습니다. 여기에는 환자 스스로 또는 보호자의 도움을 받아 시행할 수 있는 기기 사용이나 수동 기술이 포함될 수 있습니다.
또한, 유병률 증가로 인해 기도 청소에 대한 수요가 지속적으로 증가하고 있습니다. 예를 들어, 미국 국립보건원(NIH)에 따르면 낭포성 섬유증이 아닌 기관지확장증의 발병률은 인구 1,000명당 2~5명입니다. 이 질환은 노인에게 더 흔하며, 나이가 많고 허약한 환자일수록 증상이 더 심하고 중증인 경향이 있습니다. NIH에서 실시한 한 연구에서는 1,200명 이상의 기관지확장증 환자 중 50%가 65세 이상이었고, 19.1%가 75세 이상이었습니다.
또한, 심호흡 운동과 조절 호흡 기술은 기도 청소 루틴에 자주 포함됩니다. 이러한 운동은 폐활량을 개선하고 점액 배출을 촉진하는 데 도움이 될 수 있습니다. 조끼형 기도 청소 시스템이나 양압 환기 장치와 같은 기도 청소 장치가 가장 일반적으로 사용됩니다. 이러한 장치의 보급이 확대됨에 따라 기도 청소 장치에 대한 수요도 증가하고 있습니다.

지리적 분석
북미는 시장 점유율의 약 39.6%를 차지했습니다.
북미 지역은 주요 기업들의 강력한 입지와 FDA 승인 증가로 인해 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상됩니다. 북미, 특히 미국은 제약 회사, 생명공학 회사, 의료기기 회사와 같은 주요 기업들의 강력한 입지로 잘 알려져 있습니다. 주요 기업들은 연구 활동과 임상 시험에 적극적으로 참여하여 새로운 치료제를 출시하고 있습니다.
또한, 이 지역의 연구 활동 증가는 더욱 발전된 치료 옵션으로 이어지고 있으며, 이러한 새로운 치료제에 대한 FDA 승인도 지속적으로 증가하고 있습니다. 예를 들어, 2022년 4월 21일, 미국 식품의약국(FDA)은 녹농균(P. aeruginosa)에 감염된 비낭포성 섬유증 기관지확장증(NCFB) 성인 환자의 폐 악화 발생률 감소를 위한 콜리스티메테이트 나트륨 분말 분무액(CMS I-neb)에 대해 혁신 치료제 지정을 승인했습니다.

경쟁 환경
비낭포성 섬유증 기관지확장증(NCFB) 치료 시장의 주요 글로벌 업체로는 Insmed Incorporated, Johari Digital Healthcare Ltd., HMS Medical Systems, Merck & Co., Inc., Baxter International Inc., Ralington Pharma LLP, AdvaCare Pharma, Pfizer Inc., Life Care Systems, VIVAN Life Sciences 등이 있습니다.
COVID-19 영향 분석
COVID-19 팬데믹은 전 세계 비낭포성 섬유증 기관지확장증(NCFB) 치료 시장에 상당한 영향을 미쳤습니다. 팬데믹으로 인해 진행 중인 임상 시험이 중단되고 새로운 시험 시작이 지연되었습니다. 이는 NCFB에 대한 새로운 치료법의 개발 및 승인에 영향을 미쳤습니다. 팬데믹은 원격으로 의료 서비스를 제공하는 수단으로서 원격 의료의 도입을 가속화했습니다. 이러한 변화는 정기적인 추적 관찰 및 처방전 갱신을 위한 화상 상담으로 NCFB 관리 방식에 영향을 미칠 수 있습니다. 또한 팬데믹은 이러한 치료제 및 의료기기의 전 세계적인 공급망에 차질을 초래했습니다.

시장 세분화
치료 유형별
• 물리치료
• 예방접종
o 폐렴구균 예방접종
o 인플루엔자 예방접종
• 기도 청소
• 폐 재활
• 항생제
o 겐타마이신
o 세프타지딤
o 콜리스틴
o 시프로플록사신
o 기타
• 마크롤리드계 항생제
o 에리스로마이신
o 클래리트로마이신
o 록시트로마이신
o 아지트로마이신
o 기타
• 경구 스테로이드
• 기관지 확장제
o 속효성 베타2 작용제(SABA)
o 장효성 베타2 작용제(LABA)
• 기타
투여 경로별
• 경구
• 비강 투여
• 정맥 주사
• 기타
판매 채널별
• 유통 채널
o 병원 약국
o 소매 약국
o 온라인 약국
• 최종 사용자
o 병원
o 전문 클리닉
o 재활 센터
o 물리치료 센터
o 백신 접종 센터
o 기타
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 스페인
o 이탈리아
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
보고서 구매 이유

• 치료 유형, 투여 경로, 판매 채널 및 지역별 비낭포성 섬유증 기관지확장증(NCFB) 치료 시장의 글로벌 세분화를 시각화하고 주요 상업 자산 및 플레이어를 파악하기 위해

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 식별하기 위해
• 모든 세그먼트를 포함한 비낭포성 섬유증 기관지확장증(NCFB) 치료 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트

• 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석이 포함된 PDF 보고서 • 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 자료를 엑셀 파일로 제공합니다.
글로벌 비낭포성 섬유증 기관지확장증(NCFB) 치료 시장 보고서는 약 61개의 표, 63개의 그림, 그리고 187페이지 분량으로 구성됩니다.
2023년 주요 고객층
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global non-cystic fibrosis bronchiectasis (NCFB) treatment market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period 2023-2030.
Non‐cystic fibrosis bronchiectasis (NCFB) is a chronic, progressive respiratory disorder, which is characterized by irreversibly and abnormally dilated airways, persistent cough, excessive sputum production and recurrent pulmonary infections. It can occur due to various factors, including pneumonia, abnormalities of cilia, and immune deficiencies. It most frequently affects the elderly. Patients suffering from NCFB generally experience increased morbidity and worse quality of life.
Moreover, NCFB cannot be cured but can be managed with treatment. The treatment includes airway clearance by using various types of airway clearance devices such as vest airway clearance system and positive expiratory pressure valve is most commonly used, pneumococcal and influenza vaccination, macrolides are used to reduce airway mucus secretion and viscosity, antibiotics are used to lower bacterial burden and reduce most markers of inflammation, physiotherapy, pulmonary rehabilitation and bronchodilators are also used to manage the severity of the condition.
Market Dynamics: Drivers
Increasing regulatory approvals and novel drug launches
The increasing regulatory approvals and novel drug launches are expected to drive the market over the forecast period. Regulatory approvals such as FDA approvals pave the way for new drugs and therapies to enter the market with safety. This expansion of treatment options provides patients with more choices, allowing for personalized treatment plans based on individual patient needs and characteristics. These regulatory approvals increase the trust in patients about the usage of novel drugs.
For instance, on June 8, 2020, Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, cleared that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation for brensocatib (formerly known as INS1007) for the treatment of adult patients with non-cystic fibrosis bronchiectasis (NCFB) for reducing exacerbations.
Moreover, many clinical trials are going on for the development of novel drugs that show better results in the management of the NCFB. Novel drugs often undergo testing by performing clinical trials to demonstrate their efficacy and safety. For instance, in November 2022, Renovion, Inc. cleared that the first patient had enrolled in a Phase 2 clinical study evaluating ARINA-1, an investigational nebulized therapy, to treat adults with non-CF bronchiectasis (NCFB).
Additionally, on February 22, 2022, Armata Pharmaceuticals, Inc., released that the U.S. Food and Drug Administration (FDA) has cleared Armata's Investigational New Drug (IND) application to initiate a phase 2 clinical trial of its optimized lead therapeutic candidate, AP-PA02, in a second indication, non-cystic fibrosis bronchiectasis (NCFB).
Further, the increasing prevalence of non-cystic fibrosis bronchiectasis, increasing clinical trials, increasing adoption of nebulizers, technological advancements in physiotherapy and airway clearance devices, increasing awareness and advancements in the development of novel treatment options are the factors expected to drive the market over the forecast period.
Restraints
Factors such as complications associated with the treatment drugs, the high cost of the treatment, side effects associated with physiotherapy and lack of better and appropriate treatment options, availability of alternative treatment options are expected to hamper the market.
Segment Analysis
The global non-cystic fibrosis bronchiectasis (NCFB) treatment market is segmented based on treatment type, route of administration, sales channel and region.
The airway clearance segment accounted for approximately 46.2% of the non-cystic fibrosis bronchiectasis (NCFB) treatment market share
The airway clearance segment is expected to hold the largest market share over the forecast period. There is no cure for non-cystic fibrosis bronchiectasis, but airway clearance treatment is most commonly used for the management of the disease and its severity. Patients are often trained to perform airway clearance techniques at home. This may involve the use of devices or manual techniques that can be administered independently or with the help of a caregiver.
Moreover, due to the rising prevalence, the demand for airway clearance is continuously increasing. For instance, according to the National Institute of Health (NIH), the incidence of non-cystic fibrosis bronchiectasis is 2–5 patients per 1,000 population. It is more common in the elderly and older, frailer patients tend to have a more severe and symptomatic disease. In one study performed by NIH, over 1,200 patients with bronchiectasis, 50% were over 65 years old and 19.1% were over 75 years.
Further, deep breathing exercises and controlled breathing techniques are often incorporated into airway clearance routines. These exercises can help improve lung capacity and promote the clearance of mucus. Airway clearance devices such as the vest airway clearance system and positive airway pressure devices are most commonly used. In addition, their wide adoption also increases the demand for airway clearance devices.
Geographical Analysis
North America accounted for approximately 39.6% of the market share
North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and increasing FDA approvals. North America especially the United States is very well-known for its strong presence of major players such as pharmaceutical companies, biotechnology companies and medical device companies. The presence of major players actively performing in research activities and clinical trials, which leads to the launch of novel therapeutics.
Furthermore, increasing research activities in the region leads to advanced treatment options and the FDA approvals for this novel therapeutics in the region are continuously increasing. For instance, on April 21, 2022, the Food and Drug Administration (FDA) granted Breakthrough Therapy designation to colistimethate sodium powder for nebulization solution (CMS I–neb) for the reduction in the incidence of pulmonary exacerbations in adults with non-cystic fibrosis bronchiectasis (NCFB) colonized with P. aeruginosa.
Competitive Landscape
The major global players in the non-cystic fibrosis bronchiectasis (NCFB) treatment market include Insmed Incorporated, Johari Digital Healthcare Ltd., HMS Medical Systems, Merck & Co., Inc., Baxter International Inc., Ralington Pharma LLP, AdvaCare Pharma, Pfizer Inc., Life Care Systems and VIVAN Life Sciences, among others.
COVID-19 Impact Analysis
The COVID-19 pandemic significantly impacted the global non-cystic fibrosis bronchiectasis (NCFB) treatment market. The pandemic led to disruptions in ongoing clinical trials and delays in the initiation of new trials. This impacted the development and approval of novel treatments for NCFB. The pandemic accelerated the adoption of telemedicine as a means of providing healthcare services remotely. This shift could influence the management of NCFB, with virtual consultations for routine follow-ups and prescription renewals. The pandemic also disrupted the supply chain of these treatment drugs and devices globally.
Market Segmentation
By Treatment Type
• Physiotherapy
• Vaccination
o Pneumococcal Vaccination
o Influenza Vaccination
• Airway Clearance
• Pulmonary Rehabilitation
• Antibiotics
o Gentamicin
o Ceftazidime
o Colistin
o Ciprofloxacin
o Others
• Macrolides
o Erythromycin
o Clarithromycin
o Roxithromycin
o Azithromycin
o Others
• Oral Steroids
• Bronchodilators
o SABA
o LABA
• Others
By Route Of Administration
• Oral
• Nasal
• Intravenous
• Others
By Sales Channel
• Distribution Channel
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• End-User
o Hospitals
o Specialty Clinics
o Rehabilitation Centers
o Physiotherapy Centers
o Vaccination Centers
o Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Why Purchase the Report?
• To visualize the global non-cystic fibrosis bronchiectasis (NCFB) treatment market segmentation based on treatment type, route of administration, sales channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of non-cystic fibrosis bronchiectasis (NCFB) treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global non-cystic fibrosis bronchiectasis (NCFB) treatment market report would provide approximately 61 tables, 63 figures, and 187 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Treatment Type
3.2. Snippet by Route of Administration
3.3. Snippet by Sales Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Regulatory Approvals and Novel Drug Launches
4.1.2. Restraints
4.1.2.1. High Cost of the Treatment
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Pipeline Analysis
5.6. Unmet Needs
5.7. Patent Analysis
5.8. Volume Analysis
5.9. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Treatment Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
7.1.2. Market Attractiveness Index, By Treatment Type
7.2. Physiotherapy*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Vaccination
7.3.1. Pneumococcal Vaccination
7.3.2. Influenza Vaccination
7.4. Airway Clearance
7.5. Pulmonary Rehabilitation
7.6. Antibiotics
7.6.1. Gentamicin
7.6.2. Ceftazidime
7.6.3. Colistin
7.6.4. Ciprofloxacin
7.6.5. Others
7.7. Macrolides
7.7.1. Erythromycin
7.7.2. Clarithromycin
7.7.3. Roxithromycin
7.7.4. Azithromycin
7.7.5. Others
7.8. Oral Steroids
7.9. Bronchodilators
7.9.1. SABA
7.9.2. LABA
7.10. Others
8. By Route of Administration
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Oral*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Nasal
8.4. Intravenous
8.5. Others
9. By Sales Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
9.1.2. Market Attractiveness Index, By Sales Channel
9.2. Distribution Channel*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.2.3. Hospital Pharmacies
9.2.4. Retail Pharmacies
9.2.5. Online Pharmacies
9.3. End-User
9.3.1. Hospitals
9.3.2. Specialty Clinics
9.3.3. Rehabilitation Centers
9.3.4. Physiotherapy Centers
9.3.5. Vaccination Centers
9.3.6. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Insmed Incorporated*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Johari Digital Healthcare Ltd.
12.3. HMS Medical Systems
12.4. Merck & Co., Inc.
12.5. Baxter International Inc.
12.6. Ralington Pharma LLP
12.7. AdvaCare Pharma
12.8. Pfizer Inc.
12.9. Life Care Systems
12.10. VIVAN Life Sciences
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Insmed Incorporated, 4.	Key Developments, Johari Digital Healthcare Ltd., HMS Medical Systems, Merck & Co., Inc., Baxter International Inc., Ralington Pharma LLP, AdvaCare Pharma, Pfizer Inc., Life Care Systems, VIVAN Life Sciences

표 목록 (Tables)

List of Tables

Table 1 Global Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, By Treatment Type, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, By Sales Channel, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, By Treatment Type, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 7 Global Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 8 Global Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 9 Global Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, By Sales Channel, 2022, 2026 & 2030 (US$ Million)

Table 10 Global Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, By Sales Channel, 2021-2030 (US$ Million)

Table 11 Global Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 12 Global Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, By Region, 2021-2030 (US$ Million)

Table 13 North America Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 14 North America Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 15 North America Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, By Sales Channel, 2021-2030 (US$ Million)

Table 16 North America Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 17 South America Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 18 South America Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 19 South America Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, By Sales Channel, 2021-2030 (US$ Million)

Table 20 South America Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 21 Europe Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 22 Europe Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 23 Europe Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, By Sales Channel, 2021-2030 (US$ Million)

Table 24 Europe Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 25 Asia-Pacific Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 26 Asia-Pacific Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 27 Asia-Pacific Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, By Sales Channel, 2021-2030 (US$ Million)

Table 28 Asia-Pacific Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 29 Middle East & Africa Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 30 Middle East & Africa Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 31 Middle East & Africa Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, By Sales Channel, 2021-2030 (US$ Million)

Table 32 Insmed Incorporated: Overview

Table 33 Insmed Incorporated: Product Portfolio

Table 34 Insmed Incorporated: Key Developments

Table 35 Johari Digital Healthcare Ltd.: Overview

Table 36 Johari Digital Healthcare Ltd.: Product Portfolio

Table 37 Johari Digital Healthcare Ltd.: Key Developments

Table 38 HMS Medical Systems: Overview

Table 39 HMS Medical Systems: Product Portfolio

Table 40 HMS Medical Systems: Key Developments

Table 41 Merck & Co., Inc.: Overview

Table 42 Merck & Co., Inc.: Product Portfolio

Table 43 Merck & Co., Inc.: Key Developments

Table 44 Baxter International Inc.: Overview

Table 45 Baxter International Inc.: Product Portfolio

Table 46 Baxter International Inc.: Key Developments

Table 47 Ralington Pharma LLP: Overview

Table 48 Ralington Pharma LLP: Product Portfolio

Table 49 Ralington Pharma LLP: Key Developments

Table 50 AdvaCare Pharma: Overview

Table 51 AdvaCare Pharma: Product Portfolio

Table 52 AdvaCare Pharma: Key Developments

Table 53 Pfizer Inc.: Overview

Table 54 Pfizer Inc.: Product Portfolio

Table 55 Pfizer Inc.: Key Developments

Table 56 Life Care Systems: Overview

Table 57 Life Care Systems: Product Portfolio

Table 58 Life Care Systems: Key Developments

Table 59 VIVAN Life Sciences: Overview

Table 60 VIVAN Life Sciences: Product Portfolio

Table 61 VIVAN Life Sciences: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, 2021-2030 (US$ Million)

Figure 2 Global Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 3 Global Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 4 Global Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Share, By Sales Channel, 2022 & 2030 (%)

Figure 5 Global Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Share, By Region, 2022 & 2030 (%)

Figure 6 Global Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Y-o-Y Growth, By Treatment Type, 2022-2030 (%)

Figure 7 Physiotherapy Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, 2021-2030 (US$ Million)

Figure 8 Vaccination Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, 2021-2030 (US$ Million)

Figure 9 Airway Clearance Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, 2021-2030 (US$ Million)

Figure 10 Pulmonary Rehabilitation Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, 2021-2030 (US$ Million)

Figure 11 Antibiotics Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, 2021-2030 (US$ Million)

Figure 12 Macrolides Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, 2021-2030 (US$ Million)

Figure 13 Oral Steroids Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, 2021-2030 (US$ Million)

Figure 14 Bronchodilators Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, 2021-2030 (US$ Million)

Figure 15 Others Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, 2021-2030 (US$ Million)

Figure 16 Global Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 17 Oral Route of Administration in Global Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, 2021-2030 (US$ Million)

Figure 18 Nasal Route of Administration in Global Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, 2021-2030 (US$ Million)

Figure 19 Intravenous Route of Administration in Global Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, 2021-2030 (US$ Million)

Figure 20 Others Route of Administration in Global Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, 2021-2030 (US$ Million)

Figure 21 Global Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Y-o-Y Growth, By Sales Channel, 2022-2030 (%)

Figure 22 Distribution Channel Sales Channel in Global Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, 2021-2030 (US$ Million)

Figure 23 End-User Sales Channel in Global Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, 2021-2030 (US$ Million)

Figure 24 Global Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 25 North America Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, 2021-2030 (US$ Million)

Figure 26 Asia-Pacific Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, 2021-2030 (US$ Million)

Figure 27 Europe Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, 2021-2030 (US$ Million)

Figure 28 South America Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, 2021-2030 (US$ Million)

Figure 29 Middle East and Africa Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, 2021-2030 (US$ Million)

Figure 30 North America Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, 2021-2030 (US$ Million)

Figure 31 North America Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 32 North America Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 33 North America Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Share, By Sales Channel, 2022 & 2030 (%)

Figure 34 North America Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 35 South America Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, 2021-2030 (US$ Million)

Figure 36 South America Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 37 South America Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 38 South America Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Share, By Sales Channel, 2022 & 2030 (%)

Figure 39 South America Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 40 Europe Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, 2021-2030 (US$ Million)

Figure 41 Europe Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 42 Europe Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 43 Europe Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Share, By Sales Channel, 2022 & 2030 (%)

Figure 44 Europe Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 45 Asia-Pacific Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, 2021-2030 (US$ Million)

Figure 46 Asia-Pacific Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 47 Asia-Pacific Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 48 Asia-Pacific Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Share, By Sales Channel, 2022 & 2030 (%)

Figure 49 Asia-Pacific Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 50 Middle East & Africa Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Value, 2021-2030 (US$ Million)

Figure 51 Middle East & Africa Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 52 Middle East & Africa Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 53 Middle East & Africa Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market Share, By Sales Channel, 2022 & 2030 (%)

Figure 54 Insmed Incorporated: Financials

Figure 55 Johari Digital Healthcare Ltd.: Financials

Figure 56 HMS Medical Systems: Financials

Figure 57 Merck & Co., Inc.: Financials

Figure 58 Baxter International Inc.: Financials

Figure 59 Ralington Pharma LLP: Financials

Figure 60 AdvaCare Pharma: Financials

Figure 61 Pfizer Inc.: Financials

Figure 62 Life Care Systems: Financials

Figure 63 VIVAN Life Sciences: Financials

2023년부터 2030년까지 전 세계 비낭포성 섬유증 기관지확장증(NCFB) 치료 시장 전망

Global Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market - 2023-2030